However, in rats with obesity-related nephropathy, linagliptin reduced damage to the glomerular filtration barrier and proteinuria, while reducing DPP-4 activity in kidney tissue and increasing plasma levels of GLP-1 and SDF-1α [69]. This evidence concerns the gene GLP1R and kidney disorder.